Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has recently been approved for the symptomatic treatment of arthritis. In some clinical studies, doses of 400 and 800 mg/day provided somewhat less efficacy compared with 200 mg/day, which suggests an early ceiling effect. Using the zymosan-induced inflammation model in rats, we show that celecoxib significantly reduces paw swelling at 50 mg/kg but completely loses its anti-inflammatory efficacy at doses ≥100 mg/kg. To evaluate the underlying mechanisms, we used rat renal mesangial cells as a cell culture model. In these cells, celecoxib (50 µM) increased the interleukin Iβ stimulated nuclear translocation and DNA binding of NF-κB and facilitated the degradation of I-κB. Consequently, COX-DQG WXPRU QHFURVLV IDFWRU . 71)-α) expression were increased. The up-regulation of COX-2 and TNF-α also occurred in the spinal cord of rats treated with celecoxib (≥100 mg/kg), indicating that in vitro mechanisms were relevant in vivo. Clinically, the overexpression of COX-2 might be less important because celecoxib inhibits COX-2 enzymatically. However, the up-regulation of TNF-α and possibly other NF-κB regulated proinflammatory genes might worsen the pathophysiological processes underlying chronic arthritis.
production of prostaglandins (for review see 41) . However, inhibition of the inducible COX-2 is thought to provide the majority of the beneficial anti-inflammatory and analgesic effects (19, 32) . Therefore, great resources have been invested in developing selective inhibitors of this isoenzyme as gastrointestinal-sparing, anti-inflammatory, and analgesic drugs. Celecoxib (SC-58635) was the first selective COX-2 inhibitor approved by the U.S. Food and Drug Administration. Chemically, it is a sulfonamide and its structure is not related to previously available NSAIDs (25) . As expected, on account of its COX-2 selectivity, celecoxib causes significantly less gastrointestinal toxicity than nonselective NSAIDs (33) . In controlled clinical studies published so far, its anti-inflammatory and analgesic efficacy was comparable with that of nonselective control NSAIDs such as naproxen and diclofenac (7, 33) . However, several clinical studies revealed that an increase of the daily dosage from 200 to 400 or 800 mg did not further improve the desired analgesic and anti-inflammatory effects. The number of patients responding to the higher daily doses was even somewhat smaller than that responding to the lower dose of 200 mg (33, 34, 44) . These clinical results prompted us to speculate that celecoxib might show an early ceiling effect or a bell-shaped dose-response relationship. To test this hypothesis we assessed its anti-inflammatory effects in the zymosan-induced paw inflammation model in rats. At 50 mg/kg celecoxib significantly reduced the inflammatory paw edema. However, doses of 100 and 200 mg/kg had no anti-inflammatory effect. The underlying mechanisms were evaluated in vitro by using rat renal mesanigial cells as model. The in vitro experiments revealed that celecoxib activates the transcription factor NF-κB at high concentrations. Consequently, the transcription of NF-κB dependent genes was increased in vitro and in vivo. This finding may explain the observed loss of anti-inflammatory efficacy at high doses.
MATERIALS AND METHODS

Materials
Antibodies for rat COX-2, NF-κB, and I-κB were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). The antibody and cDNA probes for rat iNOS and COX-2 were a kind gift from Prof. J. Pfeilschifter (University of Frankfurt, Germany) (42) and Prof. D. DeWitt (Michigan State University, East Lansing) (6), respectively. Celecoxib was a gift from Prof. W. J. Wechter (Loma Linda University, Loma Linda, CA). Its identity and purity were checked by MS-and 1H NMR and was >98.5% (done by Dr. Walter Bauer, University of Erlangen, Germany, and is gratefully acknowledged). For the animal experiments the commercial capsules of celecoxib (Celebrex  ) were used.
Zymosan-evoked inflammation
We used male Sprague Dawley rats (Charles River, Sulzfeld, Germany) weighing 170-250 g. They were housed in groups of five in standard cages and maintained in climate-and lightcontrolled rooms (22 ± 0.5Û&KGDUNOLJKWF\FOH8QLODWHUDOKLQG-paw inflammation was induced by subcutaneous injection of 1.25 mg zymosan (Sigma-Aldrich, Steinheim, Germany) suspended in 100-µl phosphate buffer into the midplantar region of the right hind paw (22) . The paw volume was measured before zymosan injection (time 0) and at 0.25, 0.5, 1, 2, 4, 6, 8, 24, 30, and 96 h by using a plethysmometer (Ugo Basile, Varese, Italy) according to the manufacturer's instructions. At each time point, four measurements of the paw volume were taken, and the median was used to calculate the percentage increase of the paw volume compared with the value before zymosan injection (∆PW). At completion of the experiments, rats were deeply anesthetized and killed by cardiac puncture. The spinal cord was excised rapidly, and tissue samples from lumbar spinal cord were snap-frozen in liquid nitrogen and kept at -80°C until further analysis. In all experiments we obeyed the ethics guidelines for investigations in conscious animals, and the procedures were approved by the local Ethics Committee.
Drug treatment and data analysis
Celecoxib was suspended in a mixture of 1% soybean lecithin and 1% tylose (Fluka, Germany) in water. At 24 h before drug administration, animals were deprived of food but had free access to tap water. Doses of 10, 50, 100, and 200 mg/kg were administered by gastric gavage in a volume of 0.5 ml. Controls received the appropriate volume of vehicle. In each group, 6 to 10 rats were used. The drugs were administered 15 min before the intraplantar injection of zymosan.
To compare drug effects the area under the "paw volume increase" vs. "time"" curve (AUC ∆PW ) was calculated by the linear trapezoidal rule. Statistical evaluation was done by SPSS 9 for Windows. AUCs from 0 to 96 h were submitted to univariate analysis of variance with subsequent Bonferroni post hoc tests; α was set at 0.05.
Celecoxib plasma concentrations
Aliquots of human or rat plasma samples were extracted by solid-phase extraction as has been described previously (29) , and the eluate was analyzed for celecoxib. Calibration standards were prepared in drug-free human or rat plasma and were assayed at the beginning of each sequence. For control of inter-assay variation, spiked quality control samples in plasma were measured in each run in randomized order among samples. HPLC analysis was done by using a Jasco PU-1585 pump (Gross-Umstadt, Germany) connected to a Jasco AS 1550 autosampler. Chromatographic separations were obtained under isocratic conditions by using a Nucleosil C18 column (30 × 2 mm I.D., 3-µm particle size and 120-Å pore size). The mobile phase consisted of methanol/water/ammonia solution (25%) 50:50:0.1 v/v/v containing 2 mmol/l ammonium acetate, and 10 µl of the extracted sample was injected onto the LC-MS/MS. The flow rate was set at 0.1 ml/min and the runtime at 4 min. Celecoxib eluted after 1.6 min.
We performed MS and MS/MS analyses on a PE Sciex API 3000 ® (Toronto, Ontario, Canada) triple quadropole mass spectrometer. The instrument was operated in atmospheric pressure chemical ionization by using a turbo ion spray interface. For measurement of celecoxib the negative ion mode was chosen. High-purity nitrogen was used as nebulizer, curtain, auxiliary, and collision gas. The heated turbo gas temperature was set at 400°C. Quantitation was performed in the multiple reaction mode (MRM) by using nitrogen as the collision gas with a collision energy of 37 eV. Precursor-to-product ion transitions of m/z 382→316 for celecoxib and m/z 366→302 for the internal standard (4-[5-phenyl-3-(trifluoro-methyl)-1H-pyrazole-1-4']benzene-sulfonamide) were used for the MRM with a dwell time of 200 ms. Calibration standards were evaluated by Analyst software (version 1.1; PE Sciex, Toronto, Canada) by using a weighted linear regression (1/concentration) analysis. Linearity of the calibration curve was proven from 5 to 1000 ng/ml. The coefficient of correlation for all measured sequences was at least 0.99. The intraday and interday variability was <5%.
Cell culture
Rat renal mesangial cells (rMES; courtesy of Prof. J. Pfeilschifter, University of Frankfurt, Germany) were cultured in RPMI 1640 medium containing 10% fetal calf serum and 1% penicillin/streptomycin. Before stimulation with 1 nM interleukin-1β (IL-1β) or drug treatment, rMES cells were starved for 24 h in Dulbecco's modified Eagle medium containing 1% bovine serum albumin and 1% penicillin/streptomycin.
Analysis of PGE 2 , nitrite/nitrate, and TNF-α
We stimulated cells with IL-1β for 24 h in the absence or presence of celecoxib. PGE 2 concentrations in culture supernatants were assessed by a commercially available enzyme immunoassay (Biotrend Chemicals, Köln, Germany) according to the manufacturer's protocol. The reliable limit of quantification was 36.2 pg/ml, and the mean percentage deviation over the calibration range of 35-5000 pg/ml was less than 15%.
The release of NO was assessed by measuring concentrations of nitrite and nitrate by using the Griess method (12) . Quantities of 200 µl of each supernatant were mixed with 50 µl of 0.4% sulphanilamide in 1 N hydrochloric acid and 50 µl of 0.6% naphtylethylendiamine dihydrochloride in water. The absorbance of the mixture was measured photometrically at 540 nm. The reliable limit of quantification was 1 µM, and the mean percentage deviation over the calibration range of 1-50 µM was less than 15%.
TNF-α concentrations in cell culture supernatants and spinal cord homogenates were assessed by a commercially available enzyme immunoassay (Amersham Pharmacia Biotech, Freiburg, Germany) according to the manufacturer's protocol. The reliable limit of quantification was 10 pg/ml, and the mean percentage deviation over the calibration range of 30-2500 pg/ml was less than 15%.
EDTA pH 8.0; 1 mM EGTA pH 8.0; 2 mM DTT; 4 mM Pefabloc, 5 µg/ml Aprotinin, 10 µg/ml Leupeptin) and kept on ice for 30 min. After sonication for 10 s the suspension was centrifugated at 13,000 rpm in an Eppendorf centrifuge and the supernatant was stored at -70°C until further analysis.
Tissue samples from lumbar spinal cord were homogenized in 10 volumes of 10 mM Tris/HCl buffer, pH 7.4 containing 20 mM 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), 0.5 mM EDTA, 1 mM DTT, 0.5 mM PMSF and 1 µM Pefabloc (Alexis, Grünberg, Germany). After removal of cellular debris, the suspension was centrifuged at 40,000 g for 1 h, and the supernatant was stored at -70°C until further analysis. Protein concentrations were assessed by the Bradford method.
Preparation of nuclear and cytosolic cellular fractions
Cells were cultured and stimulated as described above. Cell pellets were resuspended in 1 ml lysis buffer I (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1 mM PMSF, 2 mM DTT), and incubated for 10 min on ice. After addition of NP-40 (final concentration 0.5%) the solution was vortexed and centrifuged at 400 g for 5 min. The supernatant was kept as the cytosolic fraction. The nuclear pellet was washed with lysis buffer I. Pellets were then resuspended in 2 vol. lysis buffer II (20 mM HEPES-KOH, pH 7.4, 600 mM KCl, 0.2 mM EDTA, 1 mM PMSF, 2 mM DTT) and incubated for 30 min on ice. After centrifugation (10,000 g, 10 min) the supernatant was diluted by the addition of 1 vol. lysis buffer III (20 mM Hepes-KOH (pH 7.4), 0.2 mM EDTA, 0.5 mM PMSF, 2 mM DTT). Glycerol was added to obtain a final concentration of 20%, and aliquots were stored at -80°C.
Western blot analysis
Proteins of cell lysates (50 µg), nuclear extracts (20 µg), or spinal cord homogenates (30 µg) were separated electrophoretically by 10% or 12% SDS-PAGE and then were transferred onto nitrocellulose membranes by semidry blotting. The membrane was incubated overnight at 4°C in blocking buffer (5% skimmed milk in PBS/0.3% Tween 20) . It was then incubated with the primary antibodies diluted 1:100 in blocking buffer for 90 min at room temperature. After it was washed in PBS/0.3% Tween 20, it was incubated for 60 min with a secondary antibody conjugated with peroxidase. Protein-antibody complexes were detected with the Enhanced Chemiluminescence System (Amersham-Pharmacia, Freiburg, Germany).
Electrophoretic mobility shift assay (EMSA)
We incubated nuclear extracts (5 µg) in 10% glycerol, 10 mM Hepes-KOH (pH 7.9), 50 mM KCl, 4 mM MgCl 2 , 4 mM Tris-HCl, 0.5 mM DTT, 0.5 mM EDTA, 1 µg BSA, 1 µg poly (dI-dC) together with 25 fmol of γ[
32 P]-ATP-labeled-oligonucleotide for 30 min at room temperature. The oligonucleotide sequence corresponds to the NF-κB binding site (5´-AGTTGAGGGGACTTTCCCAGGC-3´). For competition experiments a 100-fold molar excess of unlabeled probe was added to the reaction 15 min before addition of the radiolabeled probe. The nucleotide/protein complex was separated on a 4% native polyacrylamide gel in 0.25 × TBE (tris boric acid EDTA) buffer at 100 V at room temperature. The gel was dried and radioactive bands were detected by autoradiography.
RT-PCR
Total RNA was isolated from the cells by the method of Chomczynski (3). RT-PCR was performed with a Titan One Tube RT-PCR kit (Roche Diagnostics, Mannheim, Germany). Reverse transcription reaction was incubated at 50°C for 30 min. PCR amplification with COX-2 specific primers (FW: 5´-CTGTATCCCGCCCTGCTGGTG-3´, RV: 5´-ACTTGCGTTGATGGTGGCTGTCTT-3´) was started with an initial denaturation step at 95°C for 2 min. The samples were then denatured at 95°C for 1 min, annealed, and extended at 72°C for 5 min in 24 repetitive cycles.
Amplification of iNOS and β-actin was performed with the following primers:
in 30 repetitive cycles. Samples were denatured at 94°C for 2 min, annealed at 52°C, and elongated at 72°C for 1 min. Quantities of 20 µl of the samples were separated on 1.2% agarose gels. The amplified cDNA bands were detected by ethidium bromide staining.
Northern blot analysis
Total RNA (20 µg) was dissolved in 10 µl H 2 O, mixed with 10 µl of denaturing solution (500 µl formamide, 162 µl 37% formaldehyde, 100 µl 0.2 M MOPS [3-(N-morpholino)-propanesulfonicacid]), and incubated at 60°C for 15 min. RNA loading dye (4 µl) was added. Total RNA was separated on a 1% agarose gel containing 1% formaldehyde (80 V, 4 h). The RNA was then transferred to a nylon membrane overnight with 10× SSC (1.5 M sodium chloride, 0.15M sodium citrate) and immobilized with a UV transilluminator (254 nm, 150 mJoule).
The membrane was prehybridized for 3 h at 42°C in hybridization solution (5 ml formamide, 1 ml 20× SSC, 1 ml 10% SDS, 3 ml H2O). Probes for iNOS and COX-2 were radiolabeled by random oligonucleotide priming with the "High Prime" system (Roche Diagnostics). Hybridization was performed overnight at 42°C. The membrane was washed four times with 2× SSC/0.1% SDS (sodium dodecyl sulfate) and twice with 0.2× SSC/0.1% SDS, each time rotating for 20 min at 42°C. Autoradiography was performed by using an automated detector system (BAS 1500 of Fuji film; Raytest, Straubenhardt, Germany). 18S rRNA was detected as control for equal RNA loading.
RESULTS
Effects of celecoxib on zymosan-evoked inflammation
To investigate the anti-inflammatory efficacy of celecoxib, we assessed its effects in the zymosan-induced hind paw edema in rats. In vehicle-treated rats, intraplantar injection of 1.25 mg zymosan led to a maximum increase of the paw volume of 125.6 ± 9.1% (mean ± SE). This increase was reduced significantly in rats treated with 50 mg/kg celecoxib. At higher doses of 100 and 200 mg/kg, however, no obvious difference was found between celecoxib and vehicletreated rats. In the first 4 h, paw swelling was somewhat less prominent in celecoxib-treated rats.
In the period from 8 to 96 h, however, celecoxib led to a further increase of the paw volume compared with control animals (Fig. 1A) . For statistical comparisons, the area under the "paw volume increase" vs. "time" curves (AUC ∆PW from 0 to 96 h) was calculated and submitted to ANOVA with subsequent Bonferroni post hoc tests. The ANOVA revealed statistically significant differences in treatment means: F(4, 38) = 11.12, P < 0.001. The post hoc test revealed that 50 mg/kg celecoxib significantly reduced the paw edema compared with vehicletreated rats (P=0.019). In addition, 10 and 50 mg/kg celecoxib evoked significantly less paw swelling than 100 (P=0.023 and <0.001, respectively) or 200 mg/kg celecoxib (P=0.006 and <0.001, respectively) (Fig. 1B) . These data show that celecoxib noticeably inhibited the inflammatory response at doses of 10 to 50 mg/kg. However, merely a doubling of the most efficacious dose resulted in a complete loss of the anti-inflammatory efficacy.
Plasma concentrations
To define the concentration range to be used in cell culture experiments, we first assessed plasma concentrations in rats treated with the anti-inflammatory doses of 20 and 50 mg/kg and an ineffective anti-inflammatory dose of 200 mg/kg ( Fig. 2A) . We also determined plasma concentrations in three healthy subjects following a single oral dose of 800 mg. The individual plasma concentration time curves are shown in Figure 2B . Maximum plasma concentrations in rats were 7.6 ± 1.6 µM, 14.4 ± 1.1 µM, and 29.3 ± 1.1 µM following administration of 20, 50, and 200 mg/kg, respectively. As evident from Figure 2A , plasma concentrations in rats did not linearly increase with the dose, suggesting that gastrointestinal absorption was limited. Maximum plasma concentrations in human subjects were 3.2, 5.6, and 4.1 µM. Thus, for in vitro experiments 1, 10, and 50 µM were used. This concentration range covers the relevant in vivo concentrations.
Celecoxib inhibits PGE 2 release of stimulated cells but increases the expression of COX-2
Because celecoxib inhibits the enzymatic activity of COX-2 with an IC 50 of 3-6 nM (11), we hypothesized that the observed loss of anti-inflammatory efficacy at high doses was probably not mediated through a release of prostaglandins. To verify this we determined PGE 2 concentrations in cell lysates from rat renal mesangial cells rMES. We chose renal mesangial cells as in vitro model because they are predominantly activated by agents related to inflammation and can generate a number of inflammatory mediators and cytokines (26, 31) . Stimulation of rMES with IL-1β resulted in a significant increase of PGE 2 concentrations (P<0.001). Dexamethasone (positive control) and celecoxib significantly inhibited the IL-1β induced PGE 2 release (P<0.001 for 0.5 µM Dex and for 1, 10, and 50 µM celecoxib) (Fig. 3) . The inhibitory effect of celecoxib on PGE 2 synthesis was not reversible at high concentrations.
In parallel, the expression of COX-2 mRNA and protein was assessed. Celecoxib slightly reduced the IL-1β stimulated COX-2 mRNA and protein expression in renal mesangial cells at 1 µM, had no effect at 10 µM, but increased COX-2 mRNA and protein expression at 50 µM (Fig.  4) .
Enhanced DNA binding capacity of NF-κB after treatment with celecoxib
The transcription of the COX-2 gene is regulated by the transcription factor NF-κB. In unstimulated cells NF-κB dimers (p50/p65) are localized in the cytoplasm and sequestered by binding to the inhibitory subunit I-κB. On stimulation with inflammatory cytokines, endotoxin, chemokines, and other stimuli, I-κB is phosphorylated by I-κB kinases, subsequently ubiquitinylated, and then degraded by a proteasome complex. Phosphorylation of I-κB leads to the release of NF-κB from the inhibiting complex and translocation into the nucleus, where it binds to the promotor region of various genes, such as COX-2, and activates their transcription (for reviews see 1, 24). To find out whether the observed overexpression of COX-2 observed at high celecoxib concentrations was mediated through an enhanced activation of NF-κB, we assessed its DNA binding capacity by means of electrophoretic mobility shift assays. Figure 5 shows the results of a representative experiment. Renal mesangial cells were preincubated for 30 min with 1, 10, and 50 µM celecoxib and then were stimulated with IL-1β for another 30 min. In unstimulated control cells DNA binding of NF-κB was minimal. IL-1β treatment considerably increased the DNA binding activity of NF-κB. The specificity of the NF−κB DNA binding was confirmed by the reversal of the binding by a 100-fold molar excess of unlabeled probe (data not shown). Stimulated NF-κB-DNA binding activity was reduced by pretreatment of the cells with 1 µM celecoxib. Pretreatment with 50 µM, however, resulted in an overstimulation of NF-κB binding to its consensus site.
NF-κB translocation to the nucleus and I-κB degradation
To evaluate the level at which celecoxib affects the activation of NF-κB, we assessed its effects on the nuclear translocation of the p65 subunit of NF-κB and the degradation of I-κB. The amount of p65 and I-κB protein in nuclear and cytosolic extracts, respectively, was assessed in cells preincubated with celecoxib for 30 min and then stimulated for another 30 min with IL-1β. At the end of the stimulation period, we observed a significant increase of p65 in the nucleus (Fig. 6) . Simultaneously, the cytosolic I-κB protein signal disappeared. Preincubation with celecoxib at 1 and 10 µM had no obvious effect on nuclear concentrations of NF-κB but slightly reduced the degradation of I-κB. At 50 µM however, celecoxib enhanced the stimulated nuclear translocation of NF-κB and led to a complete degradation of cytosolic I-κB.
Effects of celecoxib on the expression of TNF-α and iNOS
To find out whether the observed overstimulation of NF-κB had a relevant effect not only on the transcription of COX-2 but also on other NF-κB regulated inflammatory genes (10, 43), we assessed TNF-α and iNOS expression in both rMES cells and in rat spinal cord, after treatment with celecoxib. Dexamethasone was used as positive control. In unstimulated rMES cells, iNOS mRNA and protein were not detected. Stimulation with IL-1β led to a strong iNOS mRNA and protein signal, which was accompanied by a significant increase of NO 2 -/NO 3 -release (P<0.001) (Fig. 7A) . Dexamethasone treatment resulted in a reduction of iNOS mRNA and protein and a significant inhibition of IL-1β stimulated NO 2 -/NO 3 -release (P=0.035). Celecoxib (50 µM) caused a slight overexpresssion of iNOS mRNA, whereas iNOS protein and NO 2 -/NO 3 -release remained unaffected.
TNF-α concentrations were determined in cell culture supernatants (Fig. 7B) . Stimulation of the cells with IL-1β led to a statistically significant increase of TNF-α release compared with unstimulated control cells (P=0.007), which was reduced in cells pretreated with dexamethasone or 1 and 10 µM celecoxib. Statistically, the difference was not significant. Pretreatment with 50 µM celecoxib, however, resulted in a further significant increase of TNF-α release compared with IL-1β stimulation alone (P=0.013), which suggests that the observed overstimulation of NF-κB resulted in an overproduction of this proinflammatory cytokine.
Expression of COX-2, iNOS, and TNF-α in rat lumbar spinal cord homogenates was assessed by Western blot analysis (COX-2, iNOS) or ELISA (TNF-α) (Fig. 8) to find out whether the celecoxib-induced overexpression of the respective proteins also occurred in vivo. Rats were treated with a single oral dose of 10, 50, 100, or 200 mg/kg celecoxib followed by an injection of 1.25 mg zymosan into one hind paw. The spinal cord was excised at 96 h. It has been shown previously that COX-2 is constitutively expressed in rat spinal cord, whereas iNOS is normally not found (2, 18). Both enzymes have been shown to be up-regulated in response to a peripheral inflammation (18, 37) . In the present study the zymosan-induced up-regulation of COX-2 protein in lumbar spinal cord was reduced in rats treated with 10 and 50 mg/kg celecoxib. This effect was abolished at doses of 100 mg/kg. At 200 mg/kg COX-2 protein levels exceeded those of placebo treated rats (Fig. 8) . The zymosan-induced iNOS protein expression in lumbar spinal cord was unaffected at 10-100 mg/kg celecoxib. At 200 mg/kg, however, iNOS expression was slightly increased. Zymosan-stimulated TNF-α production in lumbar spinal cord was not significantly altered at 10-100 mg/kg celecoxib. Treatment of the rats with 200 mg/kg celecoxib, however, resulted in a significant TNF-α increase (P=0.028). Thus, the effects of celecoxib on COX-2, iNOS, and TNFα expression in rat lumbar spinal cord were similar to those observed in cell culture, which suggests that the mechanisms observed in vitro also occurred in vivo.
DISCUSSION
Using the zymosan-induced paw edema in rats as a model of inflammation, we show in the present study that celecoxib completely loses its anti-inflammatory efficacy at high doses of 100 and 200 mg/kg. Maximum plasma concentrations obtained with the efficacious 50 mg/kg dose and the ineffective 200 mg/kg dose were in the order of 15 µM and 30 µM, respectively. Those observed in human subjects following a single 800 mg dose ranged from 3 µM to 5 µM. To cover the whole concentration range, 1, 10, and 50 µM were used in cell culture experiments to explore the underlying mechanisms. At 50 µM, celecoxib increased i) NF-κB DNA binding activity, ii) nuclear translocation of p65 (RelA), and iii) NF-κB-dependent gene transcription. We observed the latter effect also in rat lumbar spinal cord, which suggests that the mechanisms observed in vitro also occur in vivo. Thus, we provide evidence that the loss of anti-inflammatory efficacy is at least in part caused by an activation of nuclear factor κB.
In humans, maximum plasma concentrations ranged from 3 µM to 5 µM after administration of a single 800 mg dose. At this concentration range, we observed a decrease of NF-κB activity and NF-κB-dependent gene transcription in vitro, which was more pronounced at 1 µM than at 10 µM. Thus, a complete loss of anti-inflammatory efficacy is unlikely to occur at doses up to 800 mg. In contrast, an inhibition of NF-κB activity induced by low celecoxib concentrations might contribute to its anti-inflammatory efficacy. It may therefore be suggested that low doses of celecoxib leading to plasma concentrations in the range of 1 µM provide better symptom relief than do higher doses. This assumption is supported by results of controlled clinical studies published so far, which have revealed that celecoxib most effectively reduces pain and inflammation at 100 mg twice daily (8, 33, 34, 44) , whereas higher doses of 200 mg and 400 mg b.i.d. did not improve clinical symptoms further but were rather somewhat less effective (8, 33, 34, 44) . In this respect, it is important to note that effective and ineffective doses in rats were separated by a factor of only 2. Because of this narrow dose range, it appears conceivable that some NF-κB activation occurs in individual patients at daily doses of 400-800 mg. Concerning clinical symptoms, this effect is probably partly outweighed by the enzymatic inhibition of COX-2 activity so that the net effect is not a complete loss but only a lack of further improvement of the anti-inflammatory efficacy. However, it has to be considered that NF-κB not only regulates the transcription of COX-2 but also that of several other proinflammatory genes so that its activation may nevertheless aggravate the underlying inflammatory process. The observed increase of TNF-α release may be of great clinical importance because cytokine has been shown to play a key role in the inflammatory processes of the synovial membrane. TNF-α activates NF-κB in synovial cells (9) , thereby inducing the expression of proinflammatory mediators (30) and metalloproteinases, which are involved in the destruction of cartilage and bone (15) . New therapies that target TNF-α have demonstrated rapid action and substantial benefit in patients with rheumatoid arthritis (23, 40) , which further emphasizes the importance of this cytokine. Furthermore, recent evidence has suggested a direct relationship between the level of TNF-α expression in cardiac myocytes and the severity of cardiac hypertrophy and heart failure. Increasing the level of TNF-α in experimental animals was associated with left ventricular dilation and dysfunction. Thus, although the dosage of classical nonselective NSAIDs is limited by gastrointestinal toxicity, that of celecoxib might be limited by loss of efficacy and the occurrence of as yet unrecognized adverse effects in patients with heart failure.
The suggestion that NF-κB activation indeed modulates the effects of celecoxib at daily doses of 800 mg is supported further by the results of a recently published clinical study evaluating the anticarcinogenic efficacy of celecoxib in patients with familial adenomatous polyposis coli (35) . In this study only the high dose of 800 mg led to a significant reduction in the number of colorectal polyps. A daily dose of 200 mg had no significant effect. Because it has been shown that NF-κB activation determines the sensitivity of colon cancer cells to apoptosis inducing agents (4, 14, 20) , it may be hypothesized that NF-κB activation was essential for the chemopreventive efficacy of celecoxib while inhibition of COX-2 and prostaglandin release, which is also reliably achieved at low doses of celecoxib (e.g., 200 mg/d), was not sufficient.
So far, it is not known whether the observed NF-κB activation is a phenomenon that is specific for celecoxib or whether it is typical for COX-2 inhibitors. In contrast to the results obtained with celecoxib, some nonselective NSAIDs such as acetylsalicylic acid and flurbiprofen (17, 36, 37, 39) have been previously shown to inhibit the activation of NF-κB, which suggests that these contradictory effects depend on either the COX-nonselectivity or the acidic nature of classical NSAIDs. Further studies with other selective and unselective COX-2 inhibitors are needed to decide on this important question.
In summary, we have shown that celecoxib activates NF-κB at high concentrations and thereby loses its anti-inflammatory efficacy. These observations require further clinical studies to ensure an effective and safe therapy with this drug. At present, it appears reasonable to recommend not to increase the daily dose above 800 mg. 
